AstraZeneca Pharma India Ltd has received the approval from the Central Drugs Standard Control Organisation (CDSCO) to launch and import its cancer treatment Durvalumab (Imfinzi) in India. In a regulatory filing, the company noted that the approval i
Zydus Lifesciences Limited declared its intention to concentrate on creating a vaccine that covers both typhoid and shigellosis.
A total of 39 Indian pharmaceutical firms engaged with over 50 Vietnamese partners, participating in productive discussions at an ‘India-Vietnam Business-to-Business (B2B)’ meeting focused on the pharmaceutical sector...
Akums Drugs & Pharmaceuticals, India's leading contract development and manufacturing organization (CDMO), has signed a Memorandum of Understanding (MOU) with the National Institute of Food Technology, Entrepreneurship and Management – Thanjavur...
Glenmark Pharmaceuticals Ltd has also established itself in the US market by acquiring Aspen Pharma USA Inc's generic injectable Acetylcysteine. The acquisition, whose value remains confidential, aligns with Glenmark's strategy to enhance its hospita
In India, a Memorandum of Understanding (MoU) was signed by Philips, a leader in health technology, and Medtronic, a leader in medical technology, to teach and train radiologists and cardiologists in new imaging methods for structural heart disorders
The Central Drugs Standard Control Organization (CDSCO) issued a report that, in February 2025, a total of 145 drug samples tested throughout India were found to be of a different quality standard. The increase in the NSQ reports is attributed...
The Indian pharmaceutical industry has raised alarms over the potential imposition of US tariffs on pharmaceutical exports, warning that such a move could lead to increased drug costs and potential shortages for American consumers. Industry stalwarts
India had to rely on the tests by imports for estimating proteins and is now being facilitated with a technology transfer from...
Liraglutide, a GLP-1 peptide for diabetes and obesity, has been introduced in the United Kingdom (UK) by Biocon Limited, a multinational biopharmaceutical business that leads innovation. In the UK, the medication-device combination will be sold under
, CDSCO.jpg)
